Trials / Active Not Recruiting
Active Not RecruitingNCT07053137
A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.
Comparing Efficacy and Safety of Telitacicept and Belimumab in Systemic Lupus Erythematosus: A Retrospective Multicenter Cohort Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (estimated)
- Sponsor
- Yipeng Liu · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this observational study is to compare the efficacy and safety of tixocutibine and belizumab in the treatment of systemic lupus erythematosus in patients aged 18-65 years with systemic lupus erythematosus. The main question it aims to answer is: In the overall population of systemic lupus erythematosus: What is the response rate (SRI-4) of the two drugs in treating systemic lupus erythematosus? Which drug has better efficacy and safety? This study is a retrospective study. The participants will not receive any treatment.
Conditions
Timeline
- Start date
- 2025-11-30
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2025-07-08
- Last updated
- 2026-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07053137. Inclusion in this directory is not an endorsement.